Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 05:11pm CEST

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Purchased Brazil drugstore chain Drogaria Onofre last week

(Updates with details about an acquisition and other comments made during a conference call, beginning in the seventh paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

In a conference call with analysts, CVS disclosed it purchased Brazil drugstore chain Drogaria Onofre last week, though no price tag was disclosed as CVS called the deal "not financially material."

CVS will acquire 44 locations through the deal, the company's first acquisition abroad. The purchase comes more than six months after Walgreen agreed to spend $6.7 billion to buy a 45% stake in European pharmacy operator Alliance Boots.

CVS said it views Brazil as an attractive market, saying that region's health-care and pharmacy segments should grow in double digits for the next decade.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Walgreen has sought to strengthen its core business with its new loyalty-card program and by selling more private-label offerings. CVS on Wednesday indicated it is staying focused on retaining customer loyalty by launching more targeted promotions and e-mail offers.

CVS last week launched a pharmacy rewards program to promote retention and better prescription adherence. CVS has also doubled the amount of e-mails it sends and is seeing greater interest in the beauty-product deals it offers. Overall, CVS posted a 19% jump in the amount of offers redeemed by consumers last year.

CVS shares were down 0.2% to $51.61 in recent trading. The stock is up 6.7% in 2013.

 
  --Tess Stynes contributed to this article 

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH -0.18% 66.46 Delayed Quote.-7.43%
EXPRESS SCRIPTS HOLDING CO -0.92% 74.044 Delayed Quote.-2.87%
RITE AID CORPORATION -0.61% 1.64 Delayed Quote.-16.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
02:46pCVS HEALTH : Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Hel..
PR
02:31pCVS PHARMACY : Launches First Campaign Featuring Unaltered Beauty Imagery
PR
01:51pCVS HEALTH : EX-Dividend Schedule: CVS Health Has a Dividend Yield of 3.03%; Wil..
AC
04/18CVS HEALTH : Phoenix VA Health Care System, TriWest and CVS Health Mark First An..
PR
04/18CVS HEALTH : Names Marc-David Munk, MD, MPH, MHCM, as Chief Medical Officer of M..
AQ
04/17UnitedHealth earnings ease investor worries over flu season, stock up
RE
04/17CVS HEALTH : Today’s Research Reports on Trending Tickers: CVS Health and Centen..
AC
04/16Drug suppliers' shares rise as looming Amazon threat appears to ease
RE
04/16Drug suppliers' shares rise as looming Amazon threat appears to ease
RE
04/16CVS HEALTH : Appoints Kevin Hourican as President of CVS Pharmacy
PR
More news
News from SeekingAlpha
08:34aJelly Beans, Group Think, And Greenblatt's Magic Formula 
08:29a3 Cheap Dividend Stocks To Consider 
04/17Fixing Drug Costs 
04/17Why Every Investor Should Analyze Free Cash Flow 
04/16New retail chief at CVS Health 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 963 M
Net income 2018 5 749 M
Debt 2018 20 873 M
Yield 2018 3,17%
P/E ratio 2018 12,28
P/E ratio 2019 10,90
EV / Sales 2018 0,47x
EV / Sales 2019 0,44x
Capitalization 67 578 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,9 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-7.43%67 578
WALGREENS BOOTS ALLIANCE-9.16%65 708
EXPRESS SCRIPTS HOLDING CO-2.87%41 969
MCKESSON CORPORATION-4.14%30 802
AMERISOURCEBERGEN-0.85%20 374
CARDINAL HEALTH3.13%20 107